Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Miranda

Orthopaedic Surgery Brandon, FL Doctor of Osteopathy

NPI 1225202575 CMS profile 9982

305 E Brandon Blvd, Brandon, FL 33511

Open in the dashboard

General payments

$132,781

215 records reported · program years 2019–2025

Research payments

$8,629

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,639 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Michael Miranda of Brandon, FL is reported in the CMS Open Payments database as having received $132,781 across 215 general payments and $8,629 in research payments paid to them. Separately, studies naming them as principal investigator received $5,639 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,113 31
2024 General $8,060 22
2023 General $21,654 37
2022 General $29,866 32
2021 General $7,159 17
2020 General $7,774 27
2020 Research $6,460 6
2019 General $51,155 49
2019 Research $2,168 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Miranda
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Michael Miranda were reported at $7,113. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Michael Miranda Orthopaedic Surgery median Middle half National median
2019 $51,155 $644 $140–$2,844 $163
2020 $7,774 $312 $75–$1,860 $114
2021 $7,159 $520 $117–$2,495 $132
2022 $29,866 $598 $128–$2,731 $149
2023 $21,654 $461 $128–$2,264 $160
2024 $8,060 $497 $134–$2,475 $164
2025 $7,113 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OMNIlife science, Inc $65,684 63 payments
  2. Corin USA $49,760 29 payments
  3. Medical Device Business Services, Inc. $6,172 13 payments
  4. DePuy Synthes Products, Inc. $4,185 1 payment
  5. Stryker Corporation $1,686 40 payments
  6. Zimmer Biomet Holdings, Inc. $1,393 16 payments
  7. Arthrex, Inc. $700 6 payments
  8. DePuy Synthes Sales Inc. $509 6 payments
  9. Innovation Technologies Inc $446 3 payments
  10. Smith+Nephew, Inc. $367 8 payments
  11. Other $1,879 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $96,421 27 payments
  2. Travel and Lodging $24,473 29 payments
  3. Food and Beverage $11,820 158 payments
  4. Education $67 1 payment
Products named General payments · program years 2019–2025
  1. OMNIBotics 3.0 Technology - Knees $23,893 7 payments
  2. OMNIBotics 3.0 Implants $16,230 20 payments
  3. Velys Ortho-Knee $9,517 5 payments
  4. Velys Ortho-Hip $9,300 2 payments
  5. Various Products $6,507 3 payments
  6. OMNIBotics 3.0 Technology - Hips $5,128 12 payments
  7. TRIATHLON $598 13 payments
  8. TRITANIUM $552 9 payments
  9. Irrisept $446 3 payments
  10. ACTIS $434 4 payments
  11. Other $6,360 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. OMNIlife science, Inc $6,460 6 payments
  2. Corin USA $2,168 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,592

Median for Osteopathic Manipulative Medicine: 311

Drug cost

$23,095

Median for Osteopathic Manipulative Medicine: $11,323

Branded share of claims

1.8%

Median for Osteopathic Manipulative Medicine: 19.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 29 $10,891
Celecoxib Generic 125 $2,271
Enoxaparin Sodium Generic 16 $2,177
Diclofenac Sodium Generic 65 $2,130
Cephalexin Generic 203 $1,781
Ondansetron Hcl Generic 237 $1,209
Tramadol Hcl Generic 259 $770
Oxycodone Hcl Generic 191 $728
Meloxicam Generic 172 $367
Clindamycin Hcl Generic 67 $341

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$324,118

Of which drugs: $24,001

Medicare patients

599

Average age 74

Services billed

9,345

383 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 31%
Diabetes 29%
Depression 26%
Chronic kidney disease 25%
COPD 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 17 31 $12,379
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 28 98 $5,567
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 129 1,799 $1,368

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record